Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Ye Zeng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5440-6194; OpenAlex author ID A5048157906. Sources: OpenAlex.

Their work

Papers
24 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
50
Papers, trials and grants by year

2018: 4 papers · 2019: 4 papers · 2020: 3 papers · 2021: 7 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers

Papers 24

  1. NCOA6 knockdown enhances RSL3-induced ferroptosis in pancreatic cancer cells and increases the sensitivity to gemcitabine. First author DOI 10.3724/abbs.2024221↗
  2. The ACSS2-PPARD-BCAT1 axis synchronously regulates branched-chain amino acid metabolism and development in pancreatic cancer. First author DOI 10.3724/abbs.2025111↗
  3. NMI promotes tumor progression and gemcitabine resistance in pancreatic cancer via STAT3-IFIT3 axis. Co-author DOI 10.1002/mc.23645↗
  4. SMAD4 endows TGF-β1-induced highly invasive tumor cells with ferroptosis vulnerability in pancreatic cancer. First author DOI 10.1038/s41401-023-01199-z↗
  5. Hernandezine induces autophagic cell death in human pancreatic cancer cells via activation of the ROS/AMPK signaling pathway. Co-author DOI 10.1038/s41401-022-01006-1↗
  6. Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway. Co-author DOI 10.3389/fonc.2022.822039↗
  7. Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancer. Co-author DOI 10.1002/ctm2.398↗
  8. Organoid model: A new hope for pancreatic cancer treatment? Co-author DOI 10.1016/j.bbcan.2020.188466↗
  9. Hypoxic exosomal HIF-1α-stabilizing circZNF91 promotes chemoresistance of normoxic pancreatic cancer cells via enhancing glycolysis. Co-author DOI 10.1038/s41388-021-01960-w↗
  10. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. First author DOI 10.1038/s41401-020-00584-2↗
  11. FGFBP1-mediated crosstalk between fibroblasts and pancreatic cancer cells via FGF22/FGFR2 promotes invasion and metastasis of pancreatic cancer. Co-author DOI 10.1093/abbs/gmab074↗
  12. SETD8 induces stemness and epithelial-mesenchymal transition of pancreatic cancer cells by regulating ROR1 expression. Co-author DOI 10.1093/abbs/gmab140↗
  13. ALDOA inhibits cell cycle arrest induced by DNA damage via the ATM-PLK1 pathway in pancreatic cancer cells. First author DOI 10.1186/s12935-021-02210-5↗
  14. Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis. First author DOI 10.1038/s41388-020-01452-3↗
  15. Pin1 promotes pancreatic cancer progression and metastasis by activation of NF-κB-IL-18 feedback loop. Co-author DOI 10.1111/cpr.12816↗
  16. Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells. Co-author PMID 32368394↗
  17. Nutrient Stress-Dysregulated Antisense lncRNA GLS-AS Impairs GLS-Mediated Metabolism and Represses Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-18-0419↗
  18. Prognostic and diagnostic significance of galectins in pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.1186/s12935-019-1025-5↗
  19. Hypoxia-induced feedback of HIF-1α and lncRNA-CF129 contributes to pancreatic cancer progression through stabilization of p53 protein. Co-author DOI 10.7150/thno.30988↗
  20. LncRNA-MTA2TR functions as a promoter in pancreatic cancer via driving deacetylation-dependent accumulation of HIF-1α. Co-author DOI 10.7150/thno.34559↗
  21. Overexpression of MIST1 reverses the epithelial-mesenchymal transition and reduces the tumorigenicity of pancreatic cancer cells via the Snail/E-cadherin pathw… Co-author DOI 10.1016/j.canlet.2018.05.043↗
  22. Impact of age on survival of patients with pancreatic cancer after surgery: Analysis of SEER data. Co-author DOI 10.1016/j.pan.2017.11.008↗
  23. MiRNA-646-mediated reciprocal repression between HIF-1α and MIIP contributes to tumorigenesis of pancreatic cancer. Co-author DOI 10.1038/s41388-017-0082-2↗
  24. Hypoxia-induced LncRNA-BX111 promotes metastasis and progression of pancreatic cancer through regulating ZEB1 transcription. Co-author DOI 10.1038/s41388-018-0382-1↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaowu Xu · 14 shared papers, 2019–2025 · strength 2.06
  2. Shunrong Ji · 14 shared papers, 2020–2025 · strength 2.06
  3. Xianjun Yu · 13 shared papers, 2019–2025 · strength 1.89
  4. Yi Qin · 12 shared papers, 2019–2025 · strength 1.73
  5. Qifeng Zhuo · 8 shared papers, 2020–2022 · strength 0.99
  6. Wenyan Xu · 7 shared papers, 2020–2025 · strength 0.92
  7. Wensheng Liu · 8 shared papers, 2020–2022 · strength 0.91
  8. Haidi Chen · 4 shared papers, 2021–2025 · strength 0.75
  9. Haifeng Hu · 4 shared papers, 2021–2024 · strength 0.68
  10. Qiangsheng Hu · 6 shared papers, 2020–2021 · strength 0.65
  11. Chunyou Wang · 7 shared papers, 2018–2021 · strength 0.60
  12. Zheng Zhang · 5 shared papers, 2020–2021 · strength 0.53
  13. Gang Zhao · 6 shared papers, 2018–2021 · strength 0.49
  14. Zhu Zeng · 6 shared papers, 2018–2021 · strength 0.49
  15. Mengqi Liu · 4 shared papers, 2020–2021 · strength 0.43
  16. Chenjie Zhou · 2 shared papers, 2024–2025 · strength 0.43
  17. Fengyu Xu · 5 shared papers, 2018–2021 · strength 0.42
  18. Changfeng Song · 3 shared papers, 2021–2023 · strength 0.41
  19. Qiqing Sun · 4 shared papers, 2019–2020 · strength 0.40
  20. Shi-Jiang Deng · 5 shared papers, 2018–2019 · strength 0.39
  21. Mingliang Liu · 5 shared papers, 2018–2019 · strength 0.39
  22. Hai-di Chen · 2 shared papers, 2023–2024 · strength 0.37
  23. Xiaowu Xu · 2 shared papers, 2022–2024 · strength 0.34
  24. Shuai Zhu · 4 shared papers, 2018–2021 · strength 0.32
  25. Wuhan Yang · 1 shared paper, 2025 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.